Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Bliss, Judith M.; Tovey, Holly; Evans, Abigail; Holcombe, Chris; Horgan, Kieran; Mallon, Elizabeth; Vidya, Raghavan; Skene, Anthony; Dodson, Andrew; Hills, Margaret; Detre, Simone; Zabaglo, Lila; Banerji, Jane; Kilburn, Lucy; Morden, James P.; Robertson, John F. R.; Smith, Ian; Dowsett, Mitch

doi:10.1186/s13058-023-01626-3

Table 2 Univariable and multivariable linear regression results for Ki67_2week^† in patients allocated to AI by HER2 status

From: Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

	ER + HER2−							ER + HER2 +
	Univariable			Multivariable				Univariable			Multivariable
	β	Ci	p Value	β	Ci	p Value	Adjusted critical value	β	Ci	p Value	β	Ci	p Value	Adjusted critical value
PgR Status
Positive	0	–	< 0.001	0	–	< 0.001	0.014	0	–	< 0.001	0	–	0.004	0.014
Negative	0.70	0.53–0.88		0.49	0.33–0.65			0.75	0.40–1.09		0.50	0.19–0.81
Unknown	0.18	0.06–0.30		0.11	0.01–0.22			0.27	− 0.06 to 0.60		0.09	− 0.20 to 0.39
Tumour grade (baseline)
1	0	–	< 0.001					0	–	< 0.001
2	0.44	0.29–0.59						0.82	0.13–1.52
3	1.51	1.32–1.70						1.66	0.95–2.36
Not known	0.63	0.41–0.85						1.36	0.55–2.16
Tumour grade (2 week)
1	0	–	< 0.001 (0.001)*	0	–	< 0.001	0.007	0	–	< 0.001 (< 0.001)*	0	–	< 0.001	0.007
2	0.50	0.37–0.63		0.52	0.38–0.66			0.70	0.03–1.37		0.41	− 0.27 to 1.08
3	1.96	1.79–2.14		1.85	1.67–2.03			1.88	1.20–2.55		1.44	0.75–2.14
Tumour size (baseline)
0-2 cm	0	–	< 0.001 (0.001)*					0	–	0.036 (0.066)*
2-5 cm	0.33	0.22–0.44						0.36	0.07–0.65
> 5 cm	0.21	− 0.19 to 0.60						− 0.43	− 1.81 to 0.96
Tumour size (2 week)
0-2 cm	0	–	< 0.001 (0.001)*	0	–	0.224	0.035	0	–	< 0.001 (0.002)*	0	–	0.042	0.021
2-5 cm	0.23	0.12–0.34		0.02	− 0.08 to 0.13			0.63	0.34–0.93		0.34	0.07–0.61
> 5 cm	0.08	− 0.19 to 0.35		− 0.19	− 0.44 to 0.06			0.49	− 0.19 to 1.18		0.28	− 0.35 to 0.91
Histological type (baseline)
Ductal	0	–	< 0.001					0	–	0.393
Lobular	− 0.34	− 0.50 to − 0.19						− 0.41	− 1.02 to 0.19
Other	− 0.35	− 0.65 to − 0.06						− 0.06	− 0.98 to 0.86
Histological type (2 week)
Ductal	0	–	< 0.001	0	–	< 0.001	0.021	0	–	0.198	0	–	0.572	0.043
Lobular	− 0.40	− 0.54 to − 0.25		− 0.30	− 0.44 to − 0.16			− 0.40	− 1.03 to 0.23		− 0.18	− 0.72 to 0.37
Other	− 0.33	− 0.59 to − 0.07		− 0.04	− 0.28 to 0.21			− 0.80	− 2.00–0.39		− 0.43	− 1.45 to 0.60
Nodal status
N0	0	–	0.005 (0.002)	0	–	0.782	0.050	0	–	0.058 (0.191)*	0	–	0.420	0.036
N1-3	0.12	− 0.01 to 0.24		0.00	− 0.11 to 0.12			− 0.11	− 0.45 to 0.22		− 0.07	− 0.37 to 0.24
N4 +	0.28	0.10–0.47		0.06	− 0.12 to 0.24			0.40	0.01–0.79		0.19	− 0.19 to 0.57
Age group
< 60	0.15	0.00–0.30	0.265 (0.775)*	0.10	− 0.04 to 0.23	0.526	0.043	0.38	− 0.00 to 0.77	0.100 (0.985)*	0.38	0.05–0.71	0.129	0.029
60–69	0	–		0	–			0	–		0	–
70–79	0.05	− 0.09 to 0.18		0.01	− 0.11 to 0.13			0.37	0.02–0.71		0.15	− 0.15 to 0.45
80 +	0.05	− 0.13 to 0.23		0.05	− 0.12 to 0.21			0.10	− 0.46 to 0.66		0.19	− 0.29 to 0.68
Vascular invasion
Yes	0	–	< 0.001	0	–	0.014	0.029	0	–	0.101	0	–	0.670	0.050
No	−0.40	− 0.52 to − 0.28		− 0.13	− 0.25 to − 0.00			− 0.30	− 0.60 to − 0.01		0.02	− 0.27 to 0.30
Not reported	− 0.09	− 0.36 to 0.17		0.16	− 0.08 to 0.41			0.12	− 0.80 to 1.05		0.35	− 0.45 to 1.15

*Test for trend
^†Analysed as ln(Ki67 + 0.1)
Adjusted critical values calculated using Benjamini Hochberg method. Significant p values following adjustment are highlighted in bold

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us